Glumetinib
- Generic Name
- Glumetinib
- Drug Type
- Small Molecule
- Chemical Formula
- C21H17N9O2S
- CAS Number
- 1642581-63-2
- Unique Ingredient Identifier
- 7JTT036WGX
- Background
Glumetinib is under investigation in clinical trial NCT04270591 (Assess the Anti-tumor Activity and Safety of Glumetinib in Patient With Advanced C-met-positive Non-small Cell Lung Cancer).
- Indication
用于具有间质-上皮转化因子（MET）外显子14（MET-14）跳变的局部晚期或转移性非小细胞肺癌（NSCLC）的治疗。
Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
Phase 2
Not yet recruiting
- Conditions
- Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
- Interventions
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT06947291
Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients
Phase 2
Not yet recruiting
- Conditions
- Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
- Interventions
- First Posted Date
- 2025-04-03
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Shanghai JMT-Bio Inc.
- Target Recruit Count
- 390
- Registration Number
- NCT06908772
A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs
Phase 3
Recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Shanghai JMT-Bio Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT06829459
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer
Phase 2
Not yet recruiting
- Conditions
- Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression
- Interventions
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 256
- Registration Number
- NCT06525350
Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.
Phase 2
Not yet recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-06-11
- Target Recruit Count
- 91
- Registration Number
- NCT06452433
Single Dose Glumetinib in Healthy Chinese Male Subjects
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- Haihe Biopharma Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT05507294
- Locations
- 🇨🇳
Zhongshan Hositpal, Shanghai, Shanghai, China
Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- Haihe Biopharma Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT04338243
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Haihe Biopharma Co., Ltd.
- Target Recruit Count
- 183
- Registration Number
- NCT04270591
- Locations
- 🇺🇸
Norton Cancer Institute, Louisville, Kentucky, United States
🇺🇸The Oncology Institute of Hope & Innovation, Louisville, Kentucky, United States
🇯🇵Kanagawa Cancer Center, Kanagawa, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath